<DOC>
	<DOC>NCT01844505</DOC>
	<brief_summary>The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.</brief_summary>
	<brief_title>Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histologically confirmed stage III (unresectable) or stage IV melanoma Treatment na√Øve patients Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria Tumor tissue from an unresectable or metastatic site of disease for biomarker analyses Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Active brain metastases or leptomeningeal metastases Ocular melanoma Subjects with active, known or suspected autoimmune disease Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment Prior treatment with an antiProgrammed Death receptor1 (PD1), antiProgrammed Death1 ligand1 (PDL1), antiPDL2, or anticytotoxic T lymphocyte associated antigen4 (antiCTLA4) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>